Peptide science, in perspective.
Evidence explained. Sources included.Three receptor targets make an intriguing scientific story. The trials, their participants and the questions they leave open tell the fuller one.
Explore the evidenceWhat was tested? In whom? Compared with what? Our guides keep those details attached to every finding.
49 stories
Understand the growth-hormone fragment, the original mouse findings and the negative obesity trial assessment that marketing summaries often omit.
Mixed preclinical and human findings
A focused assessment of the actual mixture, the small knee-pain case series and the crucial difference between TB-500 fragments and full-length thymosin beta-4.
Limited combination evidence
A source-led look at a BPC-157 tendon study, distinguishing tissue outgrowth, cell migration and survival from human healing claims.
Predominantly preclinical
Why different growth-hormone signalling routes suggest a research question, but do not prove synergy or validate the finished CJC no-DAC and Ipamorelin mixture.
Individual compounds ≠ blend evidence
Separate no-DAC material from the albumin-binding CJC-1295 used in classic studies, and learn which pharmacology claims cannot cross that boundary.
Identity and extrapolation limits
A nomenclature-first guide that separates CJC-1295 with DAC from shorter non-DAC material and maps the limited human and analytical evidence.
Human early-phase · Analytical identity · Regulatory status
What delta sleep-inducing peptide studies measured, why a sleep-related name is not proof of efficacy, and how negative findings change the story.
Small, older human studies
Read the 2003 and 2025 Epitalon experiments, understand telomerase and ALT, and separate cultured human cells from human longevity evidence.
Cell and animal studies
Understand the distinction between a copper-binding research finding, a peptide formulation and a claim about skin outcomes.
Foundational biochemical and cellular evidence
A scientific reading of GHK-Cu, BPC-157 and TB-500 together: what the component studies say, and what a three-component blend still needs to demonstrate.
Constituent evidence; mixture unestablished
Compare two controlled oral glutathione studies and learn why a blood biomarker, an antioxidant mechanism and a health outcome are different findings.
Biochemistry and human studies
Follow a peptide from amino-acid assembly to analytical testing, with a calculated example showing why small manufacturing losses accumulate.
A practical reading method for cell experiments, animal models and human trials, including a worked example of relative and absolute effects.
A guide to Ipamorelin's early pharmacology and human PK/PD work, with clear separation from CJC-1295 and from performance claims.
Human early-phase · Preclinical
Understand the four declared components, the KPV intestinal-cell research, and why adding an ingredient creates new questions about the finished blend.
Constituent evidence; mixture unestablished
A model-specific guide to KPV nomenclature and the mainly cellular and animal evidence surrounding this short alpha-MSH-derived tripeptide.
Preclinical · Preclinical
How alpha-MSH signalling relates to pigment, what afamelanotide trials measured in EPP, and why a research vial is a different formulation.
Formulation-specific human trials
A safety-led guide to Melanotan II identity, small early human studies and the TGA's 2026 findings on unapproved, inconsistently dosed products.
Human early-phase · Regulatory status
A model-by-model guide to MOTS-C research, separating its original cellular and mouse findings from later human observational work and unresolved questions.
Preclinical · Human observational · Preclinical
Learn why an NMN or NR precursor study cannot be treated as a study of every NAD+ preparation, with a verified human trial example.
Biochemistry and intervention literature
Separate molecular identity, therapeutic-product status, personal importation and commercial supply using current Australian regulator guidance.
A guide that maps the research code PT-141 to bremelanotide while separating authorised pharmaceutical evidence from unrelated catalogue material.
Human randomised · Analytical identity
Retatrutide’s three receptor targets, published phase 2 and phase 3 obesity trials, outcome interpretation and analytical identity explained.
Human randomised · Regulatory status
A guide to Selank identity and its narrow, geographically concentrated human literature, with explicit limits on generalisation.
Human early-phase · Regulatory status
Compare selected Semax studies by model and endpoint, separating rat BDNF and gene-expression work from a small human imaging study.
Limited human and preclinical evidence
A cosmetic study tests a particular finished formula. Learn why its findings do not transfer automatically to a research vial or another route of exposure.
How SS-31/elamipretide targets mitochondrial membranes, why trial findings differ by disease, and what the 2025 US approval does and does not establish.
Preclinical · Human early-phase · Human randomised · Regulatory status
An identity-focused guide explaining why TB-500 should not be treated as a synonym for full-length thymosin beta-4 and what analytical studies actually found.
Analytical identity · Preclinical · Regulatory status
An indication-specific evidence guide to tesamorelin, separating established pharmaceutical trials from unrelated catalogue or body-composition claims.
Human randomised · Human randomised
A source-led guide to tirzepatide identity, dual-receptor pharmacology, human trial evidence and the limits of applying medicine data to research materials.
Human randomised · Analytical identity
Understand peptide bonds, sequence, proteins and steroid hormones, then learn which details actually identify a research compound.
A practical Australian price guide covering 10mg research vials, cost per labelled milligram, delivered totals and the documents to compare alongside a quote.
A reusable worksheet for Australian laboratories comparing material identity, documentation, delivered cost and unresolved supplier questions.
See APS vial prices, availability and starter-bundle contents, then compare cost per labelled mg and delivered supplier estimates.
Understand HPLC peak area, identity testing and peptide content, with a worked example and a practical report-reading checklist.
An original question-to-method reference separating identity, area purity, content, sterility and endotoxin, with a downloadable table.
Why PeptideX Research closed, how the TGA crackdown works, what PeptideX last charged against other Australian suppliers, and practical steps for refunds and scams.
A starting point for common BPC-157 questions, with primary-study examples and a clear distinction between a research finding, an analytical report and a medical claim.
Compare the molecules, the experiments behind common claims and the information needed to distinguish a single compound from a BPC-157 and TB-500 blend.
Compare route, formulation and study context without treating every oral product or research vial as interchangeable.
An evidence-reading guide to semaglutide, tirzepatide and retatrutide studies, explaining why separate trials cannot produce a simple supplier ranking.
Compare the receptor targets and selected primary studies while keeping formulation, population and trial design attached to each finding.
A source-linked crosswalk for four common naming problems, with explicit limits and a downloadable identity-resolution record.
Read metabolic studies without confusing MRI fat measurements, inflammatory biomarkers and clinical outcomes. Includes a primary-study example.
Calculate nominal mg/mL and the material mass in a laboratory aliquot, with visible formulas, unit conversions and assumptions.
A practical glossary separating compound names, forms, purity, content, concentration and evidence stages when reading research records.
A laboratory checklist for choosing a documented dissolution method, recording final volume and avoiding unsupported stability assumptions.
Distinguish dry-material storage from solution stability, follow material-specific instructions and document transport or storage deviations.
Understand why packaging format, formulation evidence and analytical documentation answer different questions when evaluating research material.
Find a compound, a named blend or its research aliases. Different vial quantities share the same evidence guide; the amount on a label does not change the underlying science. Some records describe archived catalogue formats.
| Catalogue format | SKU | Related evidence |
|---|---|---|
| Retatrutide (10mg) | PEP-007-10MG | Retatrutide |
| Retatrutide (20mg) | PEP-024-20MG | Retatrutide |
| Melanotan II (10mg) | PEP-009-10MG | Melanotan II |
| Melanotan I (10mg)Archived format | PEP-026-10MG | Melanotan I |
| GLOW Peptide Blend (70mg) | PEP-012-GLOW | TB-500BPC-157GHK-CuGLOW blend |
| BPC-157 (10mg) | PEP-011-10MG | BPC-157 |
| Semax (10mg) | PEP-008-10MG | Semax |
| Retatrutide Starter Bundle | BDL-001-RETA | Retatrutide |
| GHK-Cu (50mg) | PEP-010-50MG | GHK-Cu |
| NAD+ (500mg)Archived format | SUP-002-500MG | NAD+ |
| Epitalon (10mg)Archived format | PEP-027-10MG | Epitalon |
| SS-31 (10mg) | PEP-020-10MG | SS-31 |
| Tirzepatide (20mg) | PEP-021-20MG | Tirzepatide |
| Tirzepatide (40mg) | PEP-040-40MG | Tirzepatide |
| KPV (10mg)Archived format | PEP-022-10MG | KPV |
| Tesamorelin (20mg) | PEP-028-20MG | Tesamorelin |
| Ipamorelin (10mg) | PEP-023-10MG | Ipamorelin |
| CJC-1295 with DAC (10mg) | PEP-003-10MG | CJC-1295 |
| Selank (10mg) | PEP-013-10MG | Selank |
| MOTS-C (10mg) | PEP-014-10MG | MOTS-C |
| TB-500 (10mg)Archived format | PEP-015-10MG | TB-500 |
| MOTS-C (20mg) | PEP-029-20MG | MOTS-C |
| CJC-1295 (no DAC) (10mg) | PEP-016-10MG | CJC-1295CJC-1295 without DAC |
| CJC-1295 (no DAC) + Ipamorelin (10mg) | PEP-017-10MG | CJC-1295IpamorelinCJC no DAC + Ipamorelin |
| BPC-157 + TB-500 (10mg) | PEP-018-10MG | TB-500BPC-157BPC-157 + TB-500 |
| Retatrutide (30mg) | PEP-019-30MG | Retatrutide |
| Retatrutide (60mg)Archived format | PEP-025-60MG | Retatrutide |
| AOD-9604 (5mg) | PEP-030-5MG | AOD-9604 |
| DSIP (10mg) | PEP-031-10MG | DSIP |
| GHK-Cu (100mg) | PEP-032-100MG | GHK-Cu |
| Glutathione (600mg)Archived format | PEP-033-600MG | Glutathione |
| KLOW Peptide Blend (80mg) | PEP-034-80MG | KPVTB-500BPC-157GHK-CuKLOW blend |
| MOTS-C (40mg) | PEP-035-40MG | MOTS-C |
| PT-141 (10mg)Archived format | PEP-036-10MG | PT-141 / Bremelanotide |
| Retatrutide (15mg)Archived format | PEP-037-15MG | Retatrutide |
| Tesamorelin (5mg)Archived format | PEP-038-5MG | Tesamorelin |
| Tesamorelin (10mg) | PEP-039-10MG | Tesamorelin |
Laboratory supplies are covered by the preparation guide and concentration explainer. NAD+ is a coenzyme, not a peptide; it is included because it appears in the research catalogue.